Newborn screening for maple syrup urine disease (MSUD) relies on finding increased concentrations of the branched-chain amino acids (BCAAs) leucine, isoleucine, and valine by tandem mass spectrometry (MS/MS). D-Alloisoleucine (alloIle) is the only pathognomonic marker of MSUD, but it cannot be identified by existing screening methods because it is not differentiated from isobaric amino acids. Furthermore, newborns receiving total parenteral nutrition often have increased concentrations of BCAAs. To improve the specificity of newborn screening for MSUD and to reduce the number of diet-related falsepositive results, we developed a LC-MS/MS method for quantifying allo-Ile.
in the USA (http://genes-r-us.uthscsa.edu/nbsdisorders. htm). Increased concentrations of Leu, Ile, and Val are considered indicative of MSUD; however, abnormal concentrations of these amino acids are often observed in newborns receiving total parenteral nutrition. Furthermore, the currently employed MS/MS determination of BCAA in dried blood spots fails to differentiate between increased concentrations of the isobaric amino acids alloIle, Ile, Leu, and hydroxyproline (OH-Pro) (4 ), the latter of which is increased in the benign biochemical condition of hydroxyprolinemia (OMIM 23700). To improve the specificity of tandem mass spectrometry for the diagnosis of MSUD, we developed an LC-MS/MS method for the unequivocal identification of allo-Ile, Leu, Ile, Val, and OH-Pro and quantification of BCAAs in a single dried blood spot punch.
Materials and Methods
We purchased allo-Ile, Ile, Leu, Val, and OH-Pro standards, as well as acetonitrile (ACN), formic acid (FA), heptafluorobutyric acid (HFBA), and methanol, from Sigma Chemical Co.; isotopically labeled internal standards for allo-Ile, Leu, and Val from Cambridge Isotope Laboratories; and silent screen filter plates from Fisher Scientific. The filter paper used for sample collection was grade 903 (Whatman).
SAMPLES
The Mayo Foundation Institutional Review Board approved this study. For the validation of this method, normal control dried blood spot specimens were prepared by spotting whole blood of healthy controls on filter paper or by obtaining anonymized, leftover clinical samples initially submitted to Mayo Clinic's supplemental newborn screening program. We analyzed 560 newborn screening blood spots with normal alloIle concentrations to determine a reference interval for allo-Ile, Ile, Leu, and Val. In addition, 37 anonymized and blinded dried blood spots of patients (16 patients with an established diagnosis of MSUD and 21 normal controls) were provided by the Clinic for Special Children in Strasburg, PA, and stored at Ϫ80°C until assayed. High and low BCAA control samples were prepared by spotting blood of healthy individuals that was enriched with all 4 target BCAAs on grade 903 filter paper. Control samples were sealed in plastic bags with desiccant and stored at Ϫ20°C until analyzed.
STANDARD SOLUTIONS
We made stock solutions by dissolving each standard and internal standard in 0.1N HCl to a concentration of 1 g/L. From these stock solutions, internal standard working solutions were prepared weekly with 500 mL methanol brought to 1 L with water and diluted to a concentration of 10 mol/L. Organic mobile phase (mobile phase A) consisted of ACN with 1 mL/L FA and 0.1 mL/L HFBA. Aqueous mobile phase (mobile phase B) consisted of reverse osmosis water with the same concentrations of FA and HFBA.
SAMPLE PREPARATION
We extracted allo-Ile and other BCAAs from 3/16-inch dried blood spot punches placed in 96-well filter plates with 100 L water:methanol containing internal standard. After shaking for 30 min at room temperature on an orbital shaker, we collected eluents from filter plates by centrifugation for 2 min at 2200g into 96-well round-bottom plates. The water:methanol eluents were evaporated under a steady stream of nitrogen at ambient temperature, and dried specimens were reconstituted into 40 L of aqueous mobile phase B before transfer to autosampler vials and injection into the LC-MS/MS system.
INSTRUMENTATION AND ANALYSIS
BCAAs were detected on an LC-ESI-MS/MS (Applied Biosystems SCIEX API 3200) operating in positive multiple reaction monitoring mode at a temperature of 600°C and a source voltage of 2000 V. We performed chromatography by use of a peripheral Agilent 1100 series LC system with an Applied Biosystems AAA C18 (150 by 4.6 mm, 5 m) column that was maintained at 50°C. Sample injection volume was 2 L. After the application of a specimen to the LC column, a linear gradient was delivered at a rate of 650 L/min from an initial condition of 5% mobile phase A up to a mixture of 25% mobile phase A and 75% mobile phase B over a course of 7 min. An isocratic wash of 100% mobile phase A was held for 4 min before the column was reequilibrated back to the initial condition within 4 more minutes. Thus, the total analysis time was 15 min including column reequilibration. Parameters for the SCIEX API 3200 instrument are listed in Table 1 . The LC-MS/MS system was controlled and the concentration of allo-Ile, Leu, and Val measured by ratios of analyte peak areas to the respective internal standard peak areas of known concentration using Analyst 1.4.2 software running on a desktop PC with the Windows XP operating system. The concentration of Ile was determined by comparison of the Ile peak area to that of the isotopically labeled Leu.
SAMPLE STABILITY
Preextraction stability was assessed at several interday temperatures and conditions for 3 normal dried blood spots and 3 with BCAAs added at various concentrations to mimic the disease state. Ranges for BCAAs in these dried blood spots were from undetectable to 310 mol/L for allo-Ile, 48 to 292 mol/L for Ile, 88 to 464 mol/L for Leu, and 144 to 484 mol/L for Val. Dried blood spots were analyzed at 0, 1, 3, and 7 days after interim storage at ambient, frozen (Ϫ20°C), refrigerator (4°C), or warm (37°C) temperatures or after 2 freeze/thaw cycles.
ANALYTICAL CHARACTERISTICS
For recovery studies, 3 different healthy control blood samples were used to create dried blood spot specimens with added BCAAs: allo-Ile 5, 20, 40, and 200 mol/L; Ile 50, 100, 200, and 300 mol/L; Leu 100, 200, 300, and 500 mol/L; or Val 100, 200, 300, and 500 mol/L. Each specimen was analyzed on 3 different days. Recovery was defined as (measured amount Ϫ endogenous amount)/added amount.
We compared the LC-MS/MS method with an HPLC assay (7 ) by analyzing 37 blinded specimens in which the concentration of allo-Ile had been measured by the HPLC assay, provided by the laboratory of the Clinic for Special Children. Among the 37 samples, 16 were from patients with an established diagnosis of MSUD and 21 were from others.
REFERENCE INTERVAL
We measured allo-Ile, Ile, Leu, and Val in 541 control newborn screening dried blood spots and 19 dried blood spots from infants receiving total parenteral nutrition (TPN) over a period of 2 months.
Results

SAMPLE STABILITY
With one exception, changes in measured concentrations of BCAAs were Ͻ10% at the conditions studied through 7 days and after 2 freeze/thaw cycles ( Table 2 ). In addition, we determined the stability of specimens extracted and prepared from 3 normal and 3 enriched dried blood spots before and after 6 days at Ϫ20°C or 4°C. Analysis of the prepared specimens yielded concentrations within 9% of expected values (Table 2) .
IMPRECISION AND RECOVERY
Analysis of 10 replicate analyses on 5 specimens within the same day yielded mean (range) CVs of 1.8% (0%-4.8%) for allo-Ile [range of concentrations: undetectable (n ϭ 3) to 282 mol/L], 5.4% (3.5%-6.4%) for Ile (56 -629 mol/L), 6.0% (5.0 -8.1%) for Leu (105-596 mol/L), and 5.2% (4.2-8.0%) for Val (152-575 mol/L). We evaluated interassay imprecision using 5 specimens prepared and analyzed over 10 separate days. The mean interassay CVs (range) for the amino acids of interest were 5.6% (0%-14.6%) for 
METHOD COMPARISON
As shown in Fig. 2 , both the new assay and the HPLC assay (7 ) correctly identified patients with or without MSUD; the average difference of allo-Ile measured was Ͻ15%. Further comparison to the HPLC method revealed that the LC-MS/MS method yielded lower concentrations of allo-Ile in most samples, a finding likely related to better positive identification and resolution from potentially interfering substances afforded by the LC-MS/MS approach.
POPULATION INTERVALS
The mean and the 1st and 99th percentiles for 541 dried blood spots samples, 19 DBA samples from patients on total parenteral nutrition, and 16 MSUD patients are shown in Table 3 for allo-Ile, Ile, Leu, and Val. All 16 patients with MSUD had concentrations of allo-Ile markedly above the 99th percentile. 
Discussion
The introduction of MS/MS as a newborn screening tool has enabled the expansion of the number of biochemical genetic conditions that can be detected in asymptomatic newborns from a single dried blood spot. BCAA, other amino acids, free carnitine, and acylcarnitines are identified simultaneously in Ͻ3 min Based on instrument response to the Allo-Ile calibrator at 0.7 mol/L (signal-to-noise ϭ 8.1), the limit of detection and quantitation was set arbitrarily at 1 mol/L. ND, not detected.
after introduction of preferably derivatized blood spot extracts by flow injection into the tandem mass spectrometer (flow injection analysis, FIA). While FIA-MS/MS allows for high-throughput screening, it cannot distinguish isobaric compounds unless an appropriate liquid chromatography step is applied before the mass spectrometric analysis. Allo-Ile, Ile, Leu, and OH-Pro compose one such group of isobaric amino acids. Therefore, infants with hydroxyprolinemia, a clinically benign biochemical trait, or infants with high levels of BCAAs owing to total parenteral nutrition may be subject to unnecessary follow-up to rule out MSUD. To improve the specificity of MS/MS for the detection of MSUD and to spare families the anxiety associated with false-positive screening results (8 ), we developed a method for the quantification of allo-Ile and other BCAAs from a single dried blood spot. A number of MS/MS-based methods for quantifying amino acids from different sample types, such as plasma (9, 10 ) , serum (11 ), urine (10 ), or dried blood spots (11, 12 ) , were recently described. Although an LC-MS/MS method has been reported previously to be suitable for discriminating allo-Ile from Ile and Leu in a mixture of amino acids extracted from dried blood spots (12 ) , neither a comprehensive clinical validation nor a comparison to other methods used for quantifying allo-Ile was included in that report. The method described here allowed for successful identification of infants affected with classic MSUD among a cohort of healthy newborns. In addition, our method can be used to rapidly quantify BCAAs and their isoforms in dried blood spots for follow-up of MSUD patients already being treated. We have also shown through a blinded comparison study that the LC-MS/MS method is comparable to a previously described HPLC assay for quantifying allo-Ile in dried blood spots (7 ) . The sample preparation procedure described here is amenable to the use of 96-well plates and can be completed in less than 1 h. The analytical time of the LC-MS/MS approach is 15 min from injection of one sample to the next to allow for the chromatographic separation of each BCAA and OH-Pro (Fig. 1) . This method is sensitive, requires a small sample size, and is faster than previously published protocols using either an HPLC separation of derivatized amino acids (7, 13 ) or GC-MS (14 ) . This method is also an improvement over traditional methods that apply ion exchange chromatography and postcolumn ninhydrin derivatization, because allo-Ile at near normal concentrations is difficult to distinguish from other nearby eluting ninhydrin-sensitive amines, a complication that may be problematic in some cases (15 ) .
The possibility that sample stability or dried blood spot storage conditions might decrease the concentration of measurable MSUD biomarkers within the small dried blood spot sample was excluded by the shortterm stability studies of the target compounds at various temperatures and conditions (Table 2 ). These findings are supported by a recent study of the long-term stability of amino acids in dried blood spots, which revealed that the measurable concentration of some BCAAs, such as Leu, decreases at a slow rate of 3% per year when the samples are stored at ambient temperature (16 ) . The maximum length of storage at ambient temperature that we tested was 7 days, over which the concentration of all 4 BCAAs on average decreased by only 5.2%, a value well within the imprecision determined for this assay ( Table 2) .
Some cases of MSUD may escape early detection. Three cases were published whose combined concentration of the isobaric amino acids Leu, Ile, allo-Ile, and OHPro (XLE-OHPro) in the newborn screening samples (344, 325, and 209 mol/L, respectively) were below the cutoff applied by the performing laboratory (4, 15 ) . The 2 patients described by Bhattacharya et al. (17 ) were affected with the intermediate-severity form of MSUD, which often only reveals abnormal metabolites during metabolic stress. Determination of analyte ratios, such as the XLE-OHPro-to-phenylalanine and Val-to-phenylalanine, can be helpful when BCAAs are only moderately increased (4 ). The lowest XLEOHPro concentration determined in the newborn screening sample of a MSUD patient of which we are aware was 229 mol/L (n ϭ 111; 1st percentile of the disease range, 257 mol/L; see Region 4 Collaborative Project website, www.region4genetics.org). Although the Val concentration (194 mol/L) was also below the chosen cutoff (200 mol/L), both the XLE-OHPro-tophenylalanine ratio (5.2; abnormal Ͼ4.5) and the Valto-phenylalanine ratio (4.4; abnormal Ͼ3.0) were informative, and in our laboratory would have prompted further investigation. However, one of the MSUD cases reported by Bhattacharya et al. (15 ) had a XLE-OHPro concentration of only 209 mol/L and a XLE-OHProto-phenylalanine ratio of 3.7. That case would have been missed by our program as well, because our cutoffs for XLE-OHPro had been set at 300 mol/L and for ratio to phenylalanine, at 4.5. Based on this case report and a comparison of BCAA concentrations in healthy control newborns, babies receiving TPN, and cases with MSUD (Region 4 Collaborative Project, unpublished data), we adjusted the cutoffs for XLEOHPro to 200 mol/L, for ratio to phenylalanine to 3.5, and for Val to 140 mol/L. The cutoff for the Valto-phenylalanine ratio remained unchanged at 3.0. Following the algorithm depicted in Fig. 3 , any newborn screening result exceeding these cutoffs now triggers the second-tier assay for allo-Ile. Review of the last 20 000 newborn screening results obtained by our laboratory suggests that the second-tier test for 
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allo-Ile will then be performed on 0.45% of submitted newborn screening samples. The cutoff for allo-Ile (2 mol/L) was determined by LC-MS/MS analysis of 560 newborn screening samples, which revealed a nearly undetectable allo-Ile concentration regardless of dietary factors such as TPN. Considering that the lowest allo-Ile concentration in the 16 retrospectively studied MSUD cases was 16 mol/L, this cutoff value should be clinically adequate to prevent future falsenegative results (Table 3) .
In summary, we developed a new LC-MS/MS based method for the accurate determination of alloIle in newborn screening blood spots. Implementation of this assay as a second-tier newborn screening assay is expected to further reduce the false-positive rate and to increase the positive predictive value of newborn screening for MSUD while avoiding false-negative results. This concept has already proven successful for other critical analytes (18) (19) (20) . In addition, this assay can aid in the follow-up of treated MSUD patients by rapid determination of BCAAs including allo-Ile in dried blood spots or plasma.
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